ALHC · Alignment Healthcare, Inc. · Stock research

Current Thesis

Two weeks past a beat-and-raise, the price is lower. Alignment closed $13.96 on 2026-08-14 against $14.37 on 2026-08-07 — a fresh closing low — while RSI(14) rose from 17.9 to 24.7. Selling pressure eased; nothing was reclaimed. That combination is the cleanest read available on this name right now: the market is not repricing the operating line, it is discounting the unresolved accounting claim from 2026-07-08 and the guided second-half earnings step-down.

The narrative leg an investor would be buying here is arithmetic: press coverage of the former Chief Transformation Officer's suit puts the alleged software opex-booked-as-capex at roughly $8–10M, set against FY26 adjusted-EBITDA guidance of $145–163M raised on 2026-07-30, with Raymond James at $19 (2026-08-03) and JP Morgan at $22 (2026-08-04) both sitting above a $13.96 market. The leg requires the claim to stay small, the H2 cost trend to hold, and October's Medicare Advantage bid disclosure to show 2027 growth is not bought with benefit richness. None of those resolve on a date inside the next 30 days.

The narrative is dead. The "profitable MA disruptor re-rating" broke on 2026-07-08 (-16.7% to $20.03) and did not restart on the 2026-07-30 print, which delivered revenue +31.6% YoY, MBR 86.3% and GAAP net income $36.6M and was followed by lower closes into 2026-08-14. A narrative that cannot be revived by its own beat is not maturing; the structure that carried it to $24.56 is gone.

Bullish and bearish views on Alignment Healthcare, Inc.

The model's bull view on Alignment Healthcare, Inc. (ALHC), in brief: Q2 2026 (2026-07-30): revenue $1,335.6M, +31.6% YoY; adjusted gross profit $182.9M, +35.3% YoY; adjusted EBITDA $68.1M, +48.4% YoY; GAAP net income $36.6M versus $15.7M a year earlier. The bear view: Price rejected the print. $20.03 on 2026-07-08 → $14.37 on 2026-08-07 → $13.96 on 2026-08-14, with the 52-week high at $24.56 and the drawdown at 43.2%. Second-half earnings power was guided down inside the raise: Q3 adjusted EBITDA $20–30M versus $68.1M delivered in Q2, with… Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-30): revenue $1,335.6M, +31.6% YoY; adjusted gross profit $182.9M, +35.3% YoY; adjusted EBITDA $68.1M, +48.4% YoY; GAAP net income $36.6M versus $15.7M a year earlier. GAAP net income is not the line the complaint disputes.
• MBR 86.3% in Q2 2026, roughly 40bp better YoY and the lowest of the company's public life. It is a claims-cost ratio rather than a management-defined construct.
• FY26 guidance raised on 2026-07-30 across every line: revenue $5,195–5,225M (from $5,160–5,205M), adjusted gross profit $630–650M, adjusted EBITDA $145–163M, membership 298,000–301,000. Membership was ~294,100 at Q2, +31.5% YoY.
• Scale of the allegation as reported: roughly $8–10M of software operating expense capitalized, against a $145–163M FY26 adjusted-EBITDA guide. Small in arithmetic; the governance question is separate.
• Sell-side cut targets without leaving: Raymond James to Outperform, $19 (2026-08-03); JP Morgan maintained Overweight, $22 (2026-08-04). Both above the 2026-08-14 close of $13.96.
• Growth path restated on the 2026-07-30 call: ~20% enrollment growth targeted for 2027, new markets inside the existing state footprint, service-area expansion filings in February 2027 for 2028 entry.

Bear Case

• Price rejected the print. $20.03 on 2026-07-08 → $14.37 on 2026-08-07 → $13.96 on 2026-08-14, with the 52-week high at $24.56 and the drawdown at 43.2%.
• Second-half earnings power was guided down inside the raise: Q3 adjusted EBITDA $20–30M versus $68.1M delivered in Q2, with the CFO placing ~30% of full-year adjusted EBITDA in H2 against 40% the prior year, and a higher YoY Q3 MBR on earlier clinical hiring, higher new-member acuity and a flatter Part D slope.
• Q3 revenue guidance of $1,300–1,320M brackets the $1,315M consensus with the midpoint below it.
• The 2026-07-30 earnings call transcript contains no discussion of the capex-versus-opex allegation. Nothing management said on the record narrows the range of outcomes on it.
• The litigation overhang is still open-ended. Plaintiff-firm releases dated 2026-08-12 and 2026-08-13 are framed as continuing investigations; no class period or lead-plaintiff deadline surfaced in the coverage checked, meaning roughly five weeks after the allegation there is no verified docketed consolidated complaint and therefore no clock on resolution either way.
• The disputed metric is the same one the FY26 guide is written in. Until adjusted EBITDA is either audited-clean or restated, the guidance raise is worth less to a sceptical buyer than its headline.

Setup & Price Structure

• Reference close 2026-08-14: $13.96. Distance from the $24.56 52-week high: -43.2%. Three-month price return of -11.3%.
• RSI(14) 24.7 on 2026-08-14 versus 17.9 on 2026-08-07. Price made a lower low while the oscillator lifted — momentum decelerated, no base has formed, and no reclaim of the $14.37 area has been printed.
• The $18.50 level that framed the post-allegation breakdown is far above the market; the relevant structure now is whether the mid-$13s hold. $13.96 is the lowest verified close in this leg, so the shelf directly beneath it is untested.
• Crowding and positioning observables, stated as observables: sell-side targets of $19 and $22 both sit above the market and have been marked down twice in one week (2026-08-03, 2026-08-04) without going below spot; plaintiff-firm press releases have hit the newswire on 07-10, 07-15, 07-21, 07-24, 07-28, 08-03, 08-12 and 08-13, a continuous solicitation stream that keeps the name in retail news feeds without adding evidence; the filing feed shows no insider purchase or sale since the 2026-07-30 release, so there is no dated insider signal in either direction; and there is no earnings date inside 30 days, removing the usual event-driven bid.
• What would mark a turn is observable and has not happened: a weekly close back above $14.37 with the Q3 print still ahead would be the first evidence the tape has stopped discounting the accounting claim.

Catalyst Calendar (next 30 days)

• 2026-08-16 → 2026-09-15: no confirmed company-specific event. No earnings, no scheduled regulatory date, no disclosed conference presentation verified for this window. Anything that moves the name here is unscheduled: a docketed complaint, an 8-K, an audit-committee disclosure, or a sector utilization headline from a larger payer.
• ~2026-10 (est.) — CMS annual star-ratings release for the 2027 plan year. Sets quality-bonus revenue on the cohort being expanded.
• 2026-10-15 — Annual Enrollment Period opens (statutory 2026-10-15 to 2026-12-07). Determines the January 1 membership cohort behind the ~20% 2027 enrollment-growth target.
• ~2026-10-29 (est.) — Q3 2026 results. Tests the $20–30M adjusted-EBITDA guide against $68.1M in Q2, and is the first 10-Q that could carry formal audit-committee language on FY2024–25 software capitalization.

Elapsed catalysts

• ~2026-10 (est.) — 2027 Medicare Advantage bid and benefit-design disclosure. CEO John Kao said on the 2026-07-30 call it was too early to discuss bids and that detail comes in October. (passed 27d ago)
• ~2027-02 (est.) — service-area expansion filings for 2028 entry, per management on 2026-07-30. (passed 27d ago)

What Would Change Our Mind

The structure to watch is the mid-$13s: a weekly close below $13.50 takes out the August shelf and confirms the post-allegation downtrend has another leg, at which point the $19–22 target band is a lagging indicator rather than a valuation anchor. On the fundamental side, three specific disclosures would flip the read from "overhang without a clock" to "overhang with a number": a non-reliance 8-K or restatement of FY2024–25 capitalized software, an adjusted-EBITDA bridge in the Q3 10-Q that differs from previously reported figures, or a docketed consolidated complaint with an FY2024–FY2026 class period and a lead-plaintiff deadline where firm pages currently show none.

The constructive break is equally specific. A weekly close back above $14.37 (the 2026-08-07 close) that holds into the ~2026-10-29 print, together with Q3 adjusted EBITDA landing inside the $20–30M guide and Q3 MBR contained near the flagged clinical-hiring and acuity effects, would say the accounting claim has been priced and the operating line is being paid for again. October's benefit disclosure showing 2027 growth targeted without a materially richer supplemental benefit package would be the second leg of that.

Correlation Notes

• Trades with the Medicare Advantage complex — UnitedHealth, Humana, CVS/Aetna, Centene — on utilization and medical-cost-trend headlines. As the smallest of that cohort with the fastest membership growth (+31.5% YoY at Q2), it carries the highest sensitivity to a sector-wide cost scare regardless of its own book.
• Correlated to a fixed CMS calendar rather than to company execution: Advance Notice (~Jan/Feb), Rate Announcement (~April), star ratings (~October). Those dates move every MA plan simultaneously.
• Idiosyncratic risk currently dominates cohort beta. The 2026-07-08 -16.7% move and the failure of the 2026-07-30 beat to produce a sustained bid are both name-specific; a payer-sector rally would not obviously carry a name under an unresolved accounting allegation.
• Small-cap health-services liquidity conditions apply: the newswire flow is dominated by plaintiff-firm solicitations, which raises headline count without raising informational content.